Jennerex Treats First Patients in Phase 2 JX-594 Trial for Li...(ss is now an internationally recognized ...),Health

Date:1/12/2009

ss is now an internationally recognized biotechnology company developing several vaccines and therapeutic proteins. Green Cross will become the only seasonal influenza vaccine manufacturer in South Korea and also is developing avian influenza vaccine. In its vaccine business, Green Cross has successfully developed one of the earliest vaccines against Hepatitis B (Hepavax), the first Epidemic Hemorrhagic Fever vaccine and the world's second chicken pox vaccine. Green Cross is developing recombinant Factor VIII and Factor IX for hemophilia, Hepatitis B Immunoglobulin monoclonal antibody for liver transplantation, anticancer drugs such as Greenstatin (anti-angiogenic peptide) and modified PEG-G-CSF for neutropenia. For more information about Green Cross, please visit http://www.greencross.com.

About Rex Medical

Rex Medical, LP, based in Conshohocken, Pennsylvania, is a privately held medical device company specializing in the development, manufacturing and marketing of minimally invasive medical devices targeted towards the oncology, cardiovascular, venous access, and endosurgery markets.

'/>"/>

SOURCE Jennerex, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
2. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
3. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
4. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
5. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
6. New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
7. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
10. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2